New cocktail of drugs tested for Tough-to-Treat colon cancer
NCT ID NCT07011550
First seen Feb 19, 2026 · Last updated Jun 20, 2026 · Updated 19 times
Summary
This phase 2 trial is testing whether a combination of four drugs—BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab—can help control advanced colorectal cancer that has not responded to standard treatments. The study is for people with a specific type called microsatellite-stable colorectal cancer. Only 7 participants were planned, but the trial is currently suspended.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STANDARD OF CARE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab
What this could lead to
If it works, this could offer a new treatment option for people with a hard-to-treat form of colorectal cancer that has stopped responding to standard therapies.
What could go wrong
This is a very small, early-phase trial (only 7 participants planned) that is currently suspended. The combination may cause significant side effects, and it is unknown if it will be effective enough to move forward.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.